News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Obagi Medical Products, Inc. (OMPI) and Dongkook Pharmaceuticals Announce Launch of Obagi Nu-Derm System Skincare Products in South Korea


3/6/2007 2:58:47 AM

LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced it has received regulatory approval from the Korean Ministry of Health to market the Company’s leading prescription skincare line, the Obagi Medical Nu-Derm System™, as well as the Obagi Medical Nu-Derm Condition and Enhance System™ for use before and after popular aesthetic procedures including Botox injections and Laser resurfacing. Dongkook Pharmaceuticals, an established pharmaceuticals marketing and manufacturing company, will begin selling Obagi Medical products this week throughout South Korea under an existing exclusive agreement with the Company.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES